Ofatumumab and enteroviral encephalitis: a severe infectious complication as a class effect with anti-CD20 therapies
Published online on May 12, 2026
Abstract
Multiple Sclerosis Journal, Ahead of Print.
Background:Enteroviral encephalitis is a rare but potentially devastating infectious complication described under the anti-CD20 therapies rituximab and ocrelizumab.Case:A 37-year-old woman with multiple sclerosis (MS) on treatment with ofatumumab ...
Background:Enteroviral encephalitis is a rare but potentially devastating infectious complication described under the anti-CD20 therapies rituximab and ocrelizumab.Case:A 37-year-old woman with multiple sclerosis (MS) on treatment with ofatumumab ...